Orchid Research Laboratories Limited

Orchid Chemicals & Pharmaceuticals Limited

Uma Ramachandran

Sriram K Rajagopal

Ravikumar Tadiparthi

Gaddam Om Reddy

Virendra Kachhadia

Venkatesan Parameswaran

Ganapavarapu Veera Raghava Sharma

Sukunath Narayanan

Maruthikumar Narayanam

Sathyanarayana Gadde

Venkatesan Janarthanam

Durairaj Peter Bhakiaraj

Sathya Narayana Thara

Gopalan Balasubramanian

Shridhar Narayanan

Sanjeev Saxena

Akella Satya Surya Visweswara Srinivas

Sappanimuthu Thirunavukkarasu

Narayanan Surendran

Visweswara Akella Satya Surya Srinivas

Lolaknath Santosh Vishwakarma

Thirunavukkarasu Sappanimuthu

Kilambi Narsimhan

Siripragada Mahender Rao

Akella Satya Surya Visweswara Srinvas

Shikha Rani

Kilambi Narasimhan

Duddu Savaraiah Sharada

Rajagopalan Nirmala

Velaiah Sivasudar

Lakshmanan Manikandan

Om Reddy Gaddam

Ramachandran Balaji

Described are novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds are useful in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; atherosclerosis; cancer; cachexia; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; ARDS; psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD; bone resorption diseases; multiple sclerosis; sepsis; septic shock; toxic shock syndrome and fever. More particularly these compounds are useful as PDE4 inhibitors and are useful for treating PDE4 mediated diseases. 

Pyrimidine compounds and their uses

Novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof are described. These compounds are useful in the treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; atherosclerosis; cancer; cachexia; ischemic-induced cell-damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; asthma; COPD; bone resorption diseases; multiple sclerosis; sepsis; septic shock; toxic shock syndrome and fever. More particularly these compounds are useful as PDE4 inhibitors, and useful for treating PDE4 mediated diseases. 

Heterocycles

The present invention relates to novel heterocyclic compounds of the general formula (I), as IL-6 inhibitors, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and compositions, their metabolites and prodrugs thereof. The present invention more particularly provides novel heterocyclic compounds of the general formula (I). Also included is a method for treatment of cancer, cancer cachexia and inflammatory diseases including immunological diseases, particularly those mediated by cytokines such as IL-6, through pSTAT3 inhibition, in a mammal comprising administering an effective amount of a compound of formula (I) as described above 

Heterocyclic compounds as pSTAT3/IL-6 inhibitors

Growing community of inventors

Chennai, India

Uma Ramachandran